Clovis' Rubraca (rucaparib) was given an accelerated approval in December 2016 for advanced and pretreated ovarian cancer. However, the Colorado-based biotech still lags behind...
Dive Insight:
While California sequencing company Illumina is larger, Oxford's kept itself relevant and recently attracted new cash to fund an expansion.
Amgen's seen the sequencing...
Long known for its prowess in cardiovascular and respiratory diseases, AstraZeneca has joined its pharmaceutical peers in making a bigger play in oncology.
While the...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation...
